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Abstract  
The well-known action of the gastric hormone gastrin in stimulating gastric acid 
secretion is mediated by activation of cholecystokinin-2 receptors (CCK2R). The 
latter are expressed by a variety of cell types suggesting that gastrin is implicated in 
multiple functions. During wound healing in the stomach CCK2R may be expressed 
by myofibroblasts. We have now characterized CCK2R expression in cultured 
myofibroblasts. Immunocytochemistry showed that a relatively small proportion (1 – 
6%) of myofibroblasts expressed the receptor regardless of the region of the gut 
from which they were derived, or whether from cancer or control tissue. Activation of 
CCK2R by human heptadecapeptide gastrin (hG17) increased intracellular calcium 
concentrations in a small subset of myofibroblasts indicating the presence of a 
functional receptor. Unexpectedly, we found over 80% of cells expressing CCK2R 
were also labelled with 5-ethynyl-2´-deoxyuridine (EdU) which is incorporated into 
DNA during S-phase of the cell cycle. hG17 did not stimulated EdU incorporation but 
increased migration of both EdU-labelled and unlabelled myofibroblasts; the 
migratory response was inhibited by a CCK2R antagonist and by an inhibitor of IGF 
receptor tyrosine kinase; hG17 also increased IGF-2 transcript abundance. The data 
suggest myofibroblasts express CCK2R in a restricted period of the cell cycle during 
S-phase, and that gastrin accelerates migration of these cells; it also stimulates 
migration of adjacent cells probably through paracrine release of IGF. Together with 
previous findings, the results raise the prospect that gastrin controls the position of 
dividing myofibroblasts which may be relevant in wound healing and cancer 
progression in the gastrointestinal tract.  
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Introduction 
In recent years myofibroblasts have emerged as important determinants of mucosal 
organisation in health and disease [1]. The role of these cells in wound healing in 
many different tissues is well known [2]. In addition, however, a sheath of 
myofibroblasts lies just under the basement membrane in the gastrointestinal tract 
and is responsible for the secretion of proteins involved in extracellular matrix 
formation and turnover, as well as a range of growth factors including insulin-like 
growth factors (IGF)-1 and -2 [3,4]. In cancer, it is now clear that modified 
myofibroblasts (cancer-associated myofibroblasts, CAMs) play a role in defining the 
cancer niche and in influencing cancer progression [5]. These cells may originate by 
epithelial-mesenchymal transition [6], from inward migration of bone-marrow derived 
mesenchymal stem cells [7], or from tissue-resident cells including fibroblasts and 
pericytes [8]. The regulation of myofibroblast function remains incompletely 
understood.  
The pyloric antral hormone gastrin plays a central role in regulating gastric acid 
secretion notably by stimulating synthesis and secretion of histamine from 
enterochromaffin-like (ECL) cells which in turn stimulates acid secretion by parietal 
cells [9]. In addition, gastrin regulates the growth of the oxyntic-gland mucosa [10]. 
This is most clearly seen in the hyperplasia of ECL cells that is associated with 
hypergastrinemia and which in extreme cases when accompanied by inflammation 
or mutations of the MEN-1 gene may lead to neuroendocrine (carcinoid) tumors [11]. 
These actions of gastrin are mediated by the cholecystokinin-2 receptor (CCK2R) 
and are inhibited by CCK2R antagonists [12,13]. In addition, there is growing 
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recognition of the role of gastrin in gastrointestinal cancers including esophagus, 
stomach, pancreas and colon [14]; in some cases the evidence points to a role for 
gastrin acting at CCK2R but there is also evidence of a role for non-classical gastrin 
acting at other receptors [15,16]. 
The concept that tumors are wounds that do not heal is well recognised [17,18]. In 
this context it is notable that expression of CCK2R occurs during wound healing in 
the stomach. Schmassmann and Reubi used in situ hybridisation to show increased 
CCK2R in rat stomach following cryo-ulceration [19]; Ashurst et al. [20] then showed 
that after cryo-ulceration CCK2R expression was co-localized with -smooth muscle 
actin (-SMA) which is a biomarker for myofibroblasts [18]. The data therefore raise 
the possibility that CCK2R is expressed in activated myofibroblasts, but even so the 
significance of this is poorly understood. We now report that in many different 
gastrointestinal myofibroblasts there is transient expression of CCK2R in S-phase of 
the cell cycle. We have tested the hypothesis that gastrin regulates migration of 
these cells in keeping with a role in determining cell position after exit from the cell 
cycle. The data suggest a novel dimension to understanding how gastrin might 
control gastric mucosal architecture.   
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Materials and Methods  
Cells  
Unless otherwise stated experiments were performed on human primary gastric 
CAMs previously generated from patients undergoing surgery for gastric cancer [21]; 
some studies were also made on CAMs or myofibroblasts from tissue adjacent to 
cancers (ATMs) from colonic, pancreatic or esophageal cancer, normal tissue 
myofibroblasts (NTMs) from healthy stomach and esophagus, and myofibroblasts 
from chronic pancreatitis. The patients and the myofibroblasts obtained from them 
have all been described previously [21,22,23,24]. The work was approved by the 
Ethics Committee of the University of Szeged, Szeged, Hungary and all subjects 
gave informed consent. Myofibroblasts were cultured as described previously and 
were used between passages 3 and 10 [21,22,23]. AGS cells were obtained from 
American Type Culture Collection (Manassas, VA). Wild type AGS cells were used 
together with stably transfected clones expressing CCK2R [25]. 
 
Drugs, antibodies 
 L740093 was a gift from  Dr R. Freidinger (Merck Sharpe and Dohme, Rathway, 
New Jersey), AG1024 was obtained from Calbiochem (Darmstadt, Germany), 
human unsulfated heptadecapeptide gastrin (hG17) from Bachem (St Helens, 
Merseyside, UK), Click-iT EdU Imaging kit from Invitrogen (Paisley, UK), CCK2R 
antibody from Atlas Antibodies (HPA041976; Stockholm, Sweden), fluorescein 
(FITC)-conjugated AffiniPure donkey anti-rabbit IgG was from Jackson 
ImmunoResearch (West Grove, PA),  Fluo-4 AM and Pluronic F-127 from Thermo 
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Fisher Scientific (Waltham, MA) and other chemicals from Sigma-Aldrich (Poole, 
Dorset, UK),  
 
Immunocytochemistry 
Myofibroblasts were fixed with 4% w/v paraformaldehyde (PFA) and processed for 
immunocytochemistry as previously described [23,26]. Cells were permeabilized with 
0.2% Triton X-100 in PBS followed by incubation with 5% w/v bovine serum albumin 
in PBS, and blocking with 10% v/v donkey serum. Myofibroblasts were stained with a 
CCK2R polyclonal antibody (1:200, overnight, 4°C) followed by incubation with FITC-
conjugated anti-rabbit secondary antibody (1:400, 1h, ambient temperature). In some 
experiments, cells were incubated in SF medium or hG17 (10nM, 24 h) and stained 
with an antibody to caspase-3 (New England Biolabs, Hertfordshire, UK). Slides 
were mounted in Vectashield with 4′,6-diamidino-2-phenylindole dihydrochloride 
(DAPI) and images were acquired using a Zeiss Axioplan-2 fluorescence microscope 
(Zeiss Vision, Welwyn Garden City, UK). Images were recorded at 10x and 43x 
magnification using AxioVision software version 4.9.1. 
 
Microarray data 
Microarray data on pairs of CAMs and corresponding ATMs from 13 gastric cancer 
patients have previously been deposited at 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE44740. The TNM 
classification system [27] had been applied to these tumors which had shown that 
patients with early stage disease indicated by low lymph node involvement (pN0-1) 
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had significantly longer survival than those with advanced disease indicated by high 
lymph node involvement (pN2-4) (51 versus 12 months, respectively, p < 0.01) 
[21,28]. The present analysis therefore focussed on a comparison of CCK2R 
expression in these two groups. The abundance of CCK2R transcripts was 
expressed relative to GAPDH.  
 
Intracellular calcium  
Sub-confluent cells were loaded with Fluo-4 AM ester (2μM,  45 min, 37°C in HEPES 
saline buffer containing 10mM glucose, 1 mM calcium, 200μM sulphinpyrazone to 
reduce dye leakage and 25% w/v Pluronic F-127 to increase cellular uptake of dye) 
as previously described [29,30]. EGTA (1mM) was added to the solution to reduce 
spontaneous calcium activity. Myofibroblasts were stimulated with hG17 (10nM) or 
ionomycin (1M) as a positive control. Fluorescent signals were detected with a 
Leica SP2 AOBS multiphoton confocal microscope equipped with an argon-ion laser 
at 488 nm absorbance and 516 nm emission peaks. Data analysis was carried out in 
LAS X 2.0 software.  
 
EdU incorporation 
 Proliferating cells were detected using 5-ethynyl-2´-deoxyuridine (EdU) as 
previously described [21,31].  Myofibroblasts were synchronized by incubation in 
serum free (SF) media for 48h followed by treatment with medium containing 10% 
fetal bovine serum (full medium, FM), or hG17, or fresh SF, and incubation with EdU 
reagent for up to 24h. After EdU incorporation cells were fixed in paraformaldehyde 
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and processed using Click-iTTM Alexa Fluor 594 (300l) according to the 
manufacturer’s instructions. Staining of CCK2R was performed as described above.  
 
Flow cytometry 
Cultured cells were incubated in SF or FM for 48 h, or were incubated in SF with or 
without hG17 (10nM, 24h); cells were harvested and fixed in 4% PFA at 37°C for 10 
min prior to permeabilization with 90% methanol for 30 min at 4°C. For cell cycle 
analysis, cells were directly stained with DAPI (1g/ml).  In experiments aimed at 
detecting CCK2R, myofibroblasts were washed twice with 0.5% BSA dissolved in 
1xPBS and incubated with CCK2R primary antibody (1:200, 1h, ambient 
temperature) and FITC-conjugated secondary antibody (1:400, 30 min, ambient 
temperature) prior to nuclear staining with DAPI. Cells were sorted with FACS Canto 
II flow cytometer. CCK2R positive cells were separated based on fluorescence 
excited at 492 nm.  
 
Migration assays 
Transwell migration and invasion assays were performed using BD inserts or  BD 
BioCoat™ Matrigel™ invasion chambers (SLS, Nottingham, UK) with 1.3 or 2.5 x 104 
cells per insert respectively, as previously described [32]. Treatments including hG17 
with or without L740093 or AG1024 added to the lower well. In some experiments 
EdU was added to the upper well and cells were incubated overnight. Membranes 
were then processed following the EdU protocol (see above) or alternatively cells 
were stained with Quick-Diff (Reagena, Toivala, Finland). 
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qPCR 
RNA from control (SF) and gastrin (10nM, 24 h) treated myofibroblasts was 
extracted in Tri-Reagent (1.25 ml;  Sigma, Dorset, UK) according to the 
manufacturer’s instructions. Pellets were re-suspended in nuclease free water (50 l) 
and RNA (4 µg) reverse transcribed with avian myeloblastosis virus reverse 
transcriptase and oligo-dT primers (Promega). Real time PCR was carried out using 
an ABI7500 instrument (Applied Biosystems, Warrington, UK) and TaqMan 
primer/probe sets for human IGF-1, IGF-2 and GAPDH, together with Precision Plus 
2x real time PCR master mix (Primer Design, Southampton, UK) and 5’-FAM, 3’-
TAMRA double dye probes (Eurogentec, Southampton, UK). Values were 
standardized to GAPDH and assays included no-template controls and a standard 
curve as previously described [33]. Primers and probes for detection of human IGF-
1, IGF-2 and GAPDH,  cDNAs were intron-spanning and were: IGF-1: 5’-TGT ATT 
GCG CAC CCC TCA A-3’ (forward), 5’-CT CCC TCT ACT TGC GTT CTT CA-3’ 
(reverse), 5’-ACA TGC CCA AGA CCC AGA AGG AAG TAC A-3’ (probe); IGF-2, 5’-
CCG TGC TTC CGG ACA ACT T-3’ (forward), 5’-GGA CTG CTT CCA GGT GTC 
ATA TT-3’ (reverse), 5’-CCC AGA TAC CCC GTG GGC AAG TTC-3’ (probe); 
GAPDH: 5’-GCT CCT CCT GTT CGA CAG TCA-3’(forward), 5’-ACC TTC CCC ATG 
GTG TCT GA-3’ (reverse),  5’-CGT CGC CAG CCG AGC CAC A-3’ (probe). 
 
Statistics 
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Results are expressed as means ± S.E. and comparisons were made by ANOVA,  t 
test or Fisher exact test, as appropriate.  
 
Results  
CCK2R is expressed in a subset of myofibroblasts 
In initial experiments we validated the antibody used for immunocytochemical 
localization of CCK2R by comparison of wild type AGS cells (which do not express 
the receptor) with their counterparts that have been stably transfected with CCK2R, 
ie AGS-Gr cells [25]. As expected, the parental cell line was not stained; however, 
AGS-Gr cells were strongly positive (Fig. 1A). We then examined expression of 
CCK2R in a number of myofibroblast populations recovered from normal tissue, 
cancer or cancer-adjacent tissue from esophagus, stomach or colon, or pancreatitis. 
In all cases, only a subpopulation of cells were positive for CCK2R, ranging from 1 – 
6% (Fig. 1B,C). We next examined the expression of CCK2R in a microarray dataset 
( http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE44740 ) of CAMs and 
ATMs prepared from 13 patients with gastric cancer [28]. Interestingly, in patients 
with high lymph node involvement (graded pN2-4), which correlates with poor post-
operative survival, the expression of CCK2R was higher in 5 of 6 CAMs compared 
with their matched ATMs, whereas in the sub-group with low lymph node 
involvement (pN0-1)  6 of 7 CAMs expressed lower CCK2R compared with their 
matched ATMs (Fig. 1D) and the difference was statistically significant (p<0.05, 
Fisher exact test). Although the numbers are smaller, the same picture can be seen 
in the immunocytochemical data shown in Fig. 1C where expression of CCK2R was 
higher in CAMs compared with their matched ATMs from patients with high lymph 
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node involvement (S-CAM4/ATM4, pN2; S-CAM1/ATM1, pN2) while the converse is 
true for patients with low lymph node involvement (S-CAM2/ATM2, pN0; S-
CAM3/ATM3, pN1).   
 
Gastrin increases intracellular calcium in a subset of myofibroblasts 
In order to determine whether myofibroblasts are capable of mounting a functional 
response to gastrin we then examined changes in intracellular calcium on 
administration of hG17. In myofibroblasts in SF medium, there was labelling with 
Fluo-4 and no or infrequent spontaneous fluctuations in intracellular calcium. 
Administration of hG17 (10nM) produced a prompt increase in intracellular calcium in 
a sub-set of gastric CAMs (5.3 ± 1.4 % of total; 169 cells counted in three fields (Fig. 
2A,B). When the calcium ionophore was administered there was a sustained 
increase in intracellular calcium in virtually all cells.  
 
CCK2R expression is associated with the cell cycle 
To determine whether CCK2R expression was influenced by culture conditions, we 
incubated gastric CAMs in FM or SF medium and examined expression by flow 
cytometry. The subset of cells expressing CCK2R amounted to approximately 2% of 
total cells in FM, but when cells were cultured in SF medium to depress proliferation, 
the population of CCK2R-labelled cells was approximately 0.6% total (Fig. 3A). We 
then considered the hypothesis that expression of CCK2R was dependent on the cell 
cycle. As expected, cells incubated in FM exhibited significantly higher labelling with 
EdU (which is incorporated into DNA in S-phase) compared with cells in SF medium 
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(28.7 ± 0.3 vs 5.2 ± 0.6 % cells incorporating EdU, respectively, p<0.001). 
Interestingly, when we double-labelled cells with EdU and CCK2R (Fig. 3B), over 
80% of cells expressing CCK2R were found to be labelled with EdU. However, while 
the proportion of cells showing EdU incorporation increased with duration of 
incubation in FM the proportion of cells expressing CCK2R remained relatively 
constant at 2 – 3 % of total; similarly the sub-population of CCK2R positive cells that 
were not labelled with EdU (<1% of total) remained relatively constant (Fig. 3C).  
  
Gastrin does not stimulate proliferation or apoptosis of myofibroblasts 
Since CCK2R expression was associated with EdU incorporation we then asked 
whether gastrin influenced EdU incorporation. We found no significant difference in 
EdU incorporation in response to gastrin (Fig. 4A). Moreover in flow cytometry, the 
proportions of cells in G0/G1, S or G2/M phases of the cell cycle were not 
signficiantly different after incubation with hG17 (Fig. 4B,C). Gastrin also had no 
significant effect on caspase-3 labelling used as a marker of apoptosis (Fig. 4D).  
 
 
Gastrin stimulates migration and invasion of EdU-labelled and unlabelled 
gastric myofibroblasts 
Since stimulation of myofibroblasts is linked to migration and invasion, we then 
examined the effect of hG17 on these responses using Boyden chambers. There 
was a clear stimulation of both migration and invasion by hG17 that was inhibited by 
the CCK2R antagonist L740093 (Fig. 5A,B). To further characterize the migrating 
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cells we examined whether or not they incorporated EdU. There was indeed hG17-
stimulated migration of EdU labelled cells that was inhibited by L740093 (Fig. 5C,D). 
However, only about 40% of the migrating cells were labelled with EdU suggesting 
that cells expressing CCK2R were also able to activate other cells via a paracrine 
pathway. A role for IGF in mediating autocrine/paracrine signalling in myofibroblasts 
is well established [4,34], and consistent with this we found the IGF receptor tyrosine 
kinase inhibitor AG1024 supressed hG17-stimulated migration, and to a lesser 
extent invasion (Fig. 5E). Finally, in the presence of hG17 the relative abundance of 
IGF-2 transcripts was 2.1 ± 0.1 fold higher than control (p<0.05); IGF-1 transcript 
abundance was virtually undetectable in these cells.   
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Discussion  
In the normal gastrointestinal tract, CCK2R expression is localized to parietal cells, 
ECL cells, an LGR5+ antral stem cell population, smooth muscle and some enteric 
neurons [15,35]. However, in wound healing there is induction of CCK2R in cells of a 
fibroblastic lineage which may include myofibroblasts [19,20]. The main finding of the 
present study is that CCK2R is expressed in myofibroblasts from different parts of 
the gut while the cells are in S-phase of the cell cycle. The receptor appears to be 
functional and stimulation is associated with increased intracellular calcium and 
increased migration and invasion. Taken together it appears that expression of 
CCK2R may provide a mechanism that allows gastrin to determine the position of 
myofibroblasts as they progress through the cell cycle which might be particularly 
relevant during wound healing or in cancer.  
 
There are well known issues regarding interpretation of immunocytochemical studies 
with antibodies to G-protein coupled receptors (GPCRs) [36]. The antibody we 
employed was validated by the finding that wild type AGS cells (which do not 
express the receptor) were unstained while there was a strong signal in those cells 
that were stably transfected with CCK2R. Similar results (not shown) have also been 
obtained with an esophageal cell line (OE33 cells) transfected with the receptor [37]. 
These findings therefore provide direct support for the specificity of the antibody in 
localizing CCK2R.  
 
The expression of CCK2R varied from 1 to 6% of cells in different myofibroblast 
lines. However, expression of CCK2R was higher in CAMs compared with their 
corresponding ATMs in patients with advanced gastric cancer and in these 
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circumstances CAMs are known to have higher rates of proliferation [21], moreover a 
high proportion of CCK2R expressing cells incorporated EdU which corresponds to 
S-phase of the cell cycle. Although the proportion of CCK2R-expressing cells 
appears relatively low, it is similar to the proportion determined to be in S-phase from 
flow cytometry. Because EdU incorporation into DNA is stable, labelled cells 
correspond to those that were in S-phase at some stage during the labelling period. 
This is likely to account for the observation that while most CCK2R-expressing cells 
were also labelled with EdU, there were nevertheless populations of EdU labelled 
cells that were CCK2R negative (ie corresponded to cells that had since left S-phase 
and ceased expressing the receptor). The data indicate, therefore, that CCK2R 
expression in myofibroblasts is transiently associated with S-phase although in a 
formal sense we cannot exclude the possibility that there are two distinct populations 
of cells, one of which expresses CCK2R during S-phase and the other which does 
not. However, while a relatively small proportion of cells may be expressing CCK2R 
at any one point in time, expression restricted to S-phase means that all cells in this 
population do indeed express CCK2R, albeit transiently. Thus looking at overall 
frequency of expression at a single time point may be misleading.   
  
The GPCR agonists that are linked to increases in intracellular calcium are also 
mitogens for many different cell types where proliferative responses may reflect 
transactivation of the EGF receptor [25,38]. In cells of fibroblastic lineages there is 
an association between cell shape, cell cycle progression and calcium influx [39]. For 
the most part the focus of previous work in this area has been on progression from 
the checkpoint to S-phase. The selective expression of GPCRs that serve to 
increase intracellular calcium only in S-phase suggests mechanisms that are more 
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complex than previously supposed. Our observations suggest that gastrin does not 
influence either EdU incorporation during S-phase or progression through G-2 to 
mitosis. This is interesting not least because the situation appears to be different for 
some other GPCRs that exhibit cell-cycle dependent regulation of expression. For 
example the chemokine receptor CXCR3 is expressed in both S and G2-M phases in 
human microvascular endothelial cells [40]; moreover, expression of GPR19 in lung 
cancer cells is triggered by entry into S-phase and in this case seems to promote 
progression from G2 to M phase [41].  
 
The capacity of CCK2R/EdU labelled cells to respond to gastrin in chemotaxis 
assays provides direct evidence that the receptor is linked to a functional response. 
Interestingly, in these experiments there was also increased migration of unlabelled 
cells. As already mentioned, it is established that gastrin activates a number of 
paracrine signalling cascades in epithelial cells including EGF-family members, FGF-
2, IL-8 and prostaglandins [25,32,42]. The present data suggest gastrin may also 
target the IGF system which is important for mediating paracrine mechanisms 
initiated by gastrointestinal myofibroblasts [4,34]. Thus, we show here that the IGF 
receptor tyrosine kinase inhibitor blocked the paracrine effect of gastrin on migration 
of unlabelled cells, moreover gastrin increased IGF-2 transcript abundance. Whether 
or not there are other mediators requires further work.  
 
In experimental studies in rat, CCK2R is expressed during wound healing in the 
stomach [19]; in addition to epithelial cell expression the evidence indicates that 
several days after injury CCK2R is expressed in submucosal cells that express the 
myofibroblast marker, -SMA [20]. The mechanisms regulating expression have 
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been studied in cultured epithelial cells where it has been shown that serum 
starvation and gastrin itself increase CCK2R expression [20]. It now seems likely that 
different mechanisms regulate CCK2R expression in different cell types and at 
present it would appear that the association between expression and S-phase of the 
cell cycle is a property of myofibroblasts. Given the importance of myofibroblasts in 
tissue repair the expression of CCK2R may well underpin the gastrin-stimulated 
wound healing observed in animal models [19]. 
 
There has been growing interest in the role of gastrin in promoting cancer 
progression [14,43,44]. In part, this work has been directed at the non-classical 
gastrins that are thought not to act at CCK2R. The situation is not clear cut, however, 
since there may be a role for CCK2R in mediating the effects of progastrin (which is 
not a classical CCK2R agonist) on colon cancer progression [45]. To the extent that 
research in this area has been directed at CCK2R expression it has generally been 
focussed on receptor expression by either cancer cells or normal epithelial cells, 
including stem cells. The idea that CCK2R might also be transiently expressed in 
myofibroblasts adds a new dimension, which is of particular interest in view of the 
emerging consensus that the microenvironment is an important determinant of 
cancer progression [5,46,47]. 
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Legends   
Figure 1. Localization of CCK2R to a subset of myofibroblasts.  (A) Validation of 
antibody specificity: i) in wild type AGS cells, which do not express CCK2R, there is 
no signal compared with ii) a strong CCK2R signal in AGS-Gr cells which have been 
stably transfected with a receptor-encoding construct (nuclei stained blue with DAPI). 
(B) Myofibroblasts from several regions of the gastrointestinal tract express CCK2R 
in a subset of cells; i), gastric cancer associated myofibroblasts (CAMs); ii), normal 
stomach myofibroblasts. (C) Expression in myofibroblasts from different regions of 
the gut (C, colon; OE, esophagus; S, stomach; PI, chronic pancreatitis; P, pancreatic 
cancer; ATM,  adjacent tissue to cancer; NTM, normal tissue myofibroblasts).  (D) 
Abundance of CCK2R transcripts relative to GAPDH in 13 pairs of CAMs and their 
corresponding ATMs from gastric cancer patients, derived from microarray data. The 
patients are divided into two groups depending on lymph node involvement (pN0-1, n 
=7; pN2-4, n=6). Means ± SE, horizontal arrows significantly different p<0.05.   
 
Figure 2. Gastrin increases intracellular calcium in a sub-set of myofibroblasts. (A) 
Labelling of gastric CAMs with Fluo-4; i), control, ii) stimulation with hG17 (10nM), 
arrows indicate responding cells; iii) effect of ionomycin (1M). (B) hG17 (applied at 
I) stimulated a transient increase in intracellular calcium in a sub-population of 
gastric CAMs (a, b, c); ionomycin (applied at II) produced a sustained increase in 
calcium in the majority of cells.     
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Figure 3. CCK2R expression is associated with proliferation. (A) Flow cytometry 
shows a sub-population of cells cultured in full medium express CCK2R (left) but this 
population is diminished by incubation of cells in serum free medium (right) which 
suppresses proliferation. (B) CCK2R is expressed in cells that incorporate EdU; i), a 
gastric CAM incorporating EdU (red nuclei) expresses CCK2R (green) but there are 
also EdU-negative cells expressing CCK2R; ii), an example of a gastric CAM 
exhibiting EdU incorporation but not CCK2R expression; filled arrows, EdU labelled 
nuclei; open arrows, CCK2R; arrow heads, DAPI-stained nuclei in EdU- and CCK2R-
negative cells. (C) Incorporation of EdU increases with time (▼), but the proportion 
of cells expressing CCK2R and labelled with EdU (●) remains relatively constant at 2 
– 3% total; less than 1% of cells express CCK2R and are not labelled with EdU (ₒ), a 
decreasing proportion of cells are both EdU and CCK2R negative (). Means ± SE 
(n=3). 
 
Figure 4. Gastrin does not stimulate proliferation or apoptosis in myofibroblasts. (A) 
Incubation in hG17 (10nM, 24h) had no effect on EdU incorporation. (B) 
Representative flow cytometry profiles show no effect of incubation in hG17 on the 
proportion of cells in G0/G1, S or G2/M. (C) Quantification of cells in G0/G1, S or 
G2/M  by flow cytometry in three separate experiments. (D) Staining with antibody to 
caspase-3 shows no effect of hG17 (10nM, 24 h) on apoptosis. N=3, means ± SE.  
 
Figure 5. Gastrin stimulates myofibroblast migration and invasion. (A) 
Representative Boyden chamber images showing migration (top) and invasion 
(bottom) in response to hG17 (10nM), L740093 (50M), and the combination. (B) 
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hG17 stimulates both cell migration (left) and invasion (right) of myofibroblasts in 
Boyden chambers and the response is inhibited by the CCK2R antagonist, L740093; 
y-axis mean ± SE number of cells per field. (C) Some migrating cells incorporate 
EdU (blue, DAPI; red, EdU, arrows); i) scale bar 50 m, ii) 10 m. (D) hG17 
stimulates migration of EdU labelled cells and this is blocked by L740093 (y-axis 
labelled cells per field). (E) Migration (left) and invasion (right) in response to hG17 
was suppressed by the IGF-1 receptor tyrosine kinase inhibitor (AG1024, 2M). 
Horizontal arrows, p<0.05, ANOVA. 
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